FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1775296475> ?p ?o ?g. }

• W1775296475 endingPage "1" @default.
• W1775296475 startingPage "1" @default.
• W1775296475 abstract "Back to table of contents Previous article Next article Clinical and Research NewsFull AccessPsychiatrists Discuss Benefits, Risks of ECTVabren WattsVabren WattsSearch for more papers by this authorPublished Online:15 Jun 2015https://doi.org/10.1176/appi.pn.2015.6b16AbstractPatients with psychotic, geriatric, and treatment-resistant depression may be the most likely to respond to electroconvulsive therapy.During APA’s 2015 annual meeting last month, several of the world’s leading electroconvulsive therapy (ECT) practitioners led a session in which they described the effectiveness of ECT and the patients most likely to benefit from the therapy.“The biggest problem with ECT is the stigma associated with its use,” said Mount Sinai School of Medicine ECT Services Director Charles Kellner, M.D.Charles Kellner, M.D., presents data showing that ECT may be more effective than pharmacotherapies in some cases of major depressive disorder.David HathcoxECT was first introduced as a psychiatric treatment in 1938 for depression. But, by the 1960s, with the rise in available pharmacotherapies and the media’s and film industry’s portrayal of ECT as inhumane, the use of the therapy declined, Kellner said. According to Kellner, today an estimated 1,000,000 people worldwide are treated with ECT, with 100,000 people being treated in the United States. “People with the most severe form of major depressive disorder do better with ECT than any other treatment,” Kellner explained. Previous studies found ECT to be twice as effective as pharmacotherapies and two to three times more effective than transcranial magnetic stimulation at reducing symptoms of depression in patients with major depressive disorder. Kellner also presented data from a study he published in the American Journal of Psychiatry in 2005 showing that when ECT was administered over the course of six months to patients who were severely depressed, they had fewer suicidal thoughts compared with those who did not receive ECT.Kellner told the audience that ECT should not be recommended only as a last resort for patients who have failed other forms of therapy. He explained that ECT can be recommended in the most severe cases of major depressive disorder, even before pharmacotherapy. According to Peter Rosenquist, M.D., vice chair of psychiatry at Georgia Regents University, research has shown that 50 to 60 percent of people with treatment-resistant depression respond to ECT. “People with psychotic depression are the highest responders, with a response rate of 95 percent,” Rosenquist told Psychiatric News, “followed by people with geriatric depression, at 90 percent.”Peter Rosenquist, M.D., says that temporal cognitive impairment is the biggest risk associated with electroconvulsive therapy.David HathcoxBoth Kellner and Rosenquist emphasized that when determining whether someone is an ideal candidate for ECT, it is important to assess the severity and episodicity of their symptoms as well as family history of mental illness.Patients with bipolar disorder and schizophrenia may also benefit from using ECT. Previous studies have shown that combined use of ECT and the antipsychotics clozapine or flupenthixol prevents relapse of schizophrenia symptoms by an average of 60 percent. Rosenquist said that though usage rates for ECT are low in the United States for this diagnosis, schizophrenia is the primary indication for ECT in other countries. One of the main risks associated with ECT is cognitive impairment, which symptoms tend to fall within three main categories:Acute confusional state: No awareness of location and time. Symptoms may last up to three hours following ECT procedure.Antrograde amnesia: Impaired ability to retain new information. Retrograde amnesia: Impaired memory for events that occurred one to three months prior to ECT. All cognitive ability is restored after 15 days, according to Rosenquist. “ECT is just like any other therapy—there are risk and benefits,” Rosenquist told Psychiatric News. “Despite the controversy that surrounds ECT, it is a very effective treatment and one of the safest treatments for treating populations with severe mental disorders. It is important for ECT practitioners—and those who refer patients for ECT—to really understand the nature of their patients’ illness to determine whether they are good candidates and healthy enough for ECT.” ■A video interview of Rosenquist discussing ECT can be viewed here. ISSUES NewArchived" @default.
• W1775296475 created "2016-06-24" @default.
• W1775296475 creator A5062246672 @default.
• W1775296475 date "2015-06-19" @default.
• W1775296475 modified "2023-10-18" @default.
• W1775296475 title "Psychiatrists Discuss Benefits, Risks of ECT" @default.
• W1775296475 doi "https://doi.org/10.1176/appi.pn.2015.6b16" @default.
• W1775296475 hasPublicationYear "2015" @default.
• W1775296475 type Work @default.
• W1775296475 sameAs 1775296475 @default.
• W1775296475 citedByCount "0" @default.
• W1775296475 crossrefType "journal-article" @default.
• W1775296475 hasAuthorship W1775296475A5062246672 @default.
• W1775296475 hasConcept C118552586 @default.
• W1775296475 hasConcept C139719470 @default.
• W1775296475 hasConcept C15744967 @default.
• W1775296475 hasConcept C162324750 @default.
• W1775296475 hasConcept C2776412080 @default.
• W1775296475 hasConcept C2776867660 @default.
• W1775296475 hasConcept C2777330709 @default.
• W1775296475 hasConcept C2780051608 @default.
• W1775296475 hasConcept C2780733359 @default.
• W1775296475 hasConcept C542102704 @default.
• W1775296475 hasConcept C71924100 @default.
• W1775296475 hasConceptScore W1775296475C118552586 @default.
• W1775296475 hasConceptScore W1775296475C139719470 @default.
• W1775296475 hasConceptScore W1775296475C15744967 @default.
• W1775296475 hasConceptScore W1775296475C162324750 @default.
• W1775296475 hasConceptScore W1775296475C2776412080 @default.
• W1775296475 hasConceptScore W1775296475C2776867660 @default.
• W1775296475 hasConceptScore W1775296475C2777330709 @default.
• W1775296475 hasConceptScore W1775296475C2780051608 @default.
• W1775296475 hasConceptScore W1775296475C2780733359 @default.
• W1775296475 hasConceptScore W1775296475C542102704 @default.
• W1775296475 hasConceptScore W1775296475C71924100 @default.
• W1775296475 hasIssue "12" @default.
• W1775296475 hasLocation W17752964751 @default.
• W1775296475 hasOpenAccess W1775296475 @default.
• W1775296475 hasPrimaryLocation W17752964751 @default.
• W1775296475 hasRelatedWork W1776602198 @default.
• W1775296475 hasRelatedWork W2042970400 @default.
• W1775296475 hasRelatedWork W2464880069 @default.
• W1775296475 hasRelatedWork W2592342712 @default.
• W1775296475 hasRelatedWork W2732481164 @default.
• W1775296475 hasRelatedWork W2914337102 @default.
• W1775296475 hasRelatedWork W2939691803 @default.
• W1775296475 hasRelatedWork W3138243474 @default.
• W1775296475 hasRelatedWork W4205671735 @default.
• W1775296475 hasRelatedWork W2133869308 @default.
• W1775296475 hasVolume "50" @default.
• W1775296475 isParatext "false" @default.
• W1775296475 isRetracted "false" @default.
• W1775296475 magId "1775296475" @default.
• W1775296475 workType "article" @default.